Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare - Summary - MDSpire

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

  • By

  • Junfeng Ma

  • Peng Yan

  • Chonghua Liu

  • Yuanyuan Wang

  • June 8, 2026

  • 0 min

Share

Objective:

To describe the management of advanced NSCLC patients with concurrent uncommon EGFR mutations, high PD-L1 expression, and active autoimmune disease.

Key Findings:
  • The patient had a non-classical EGFR mutation and high PD-L1 expression.
  • Initial immunotherapy led to a significant flare of rheumatoid arthritis, necessitating its discontinuation.
  • Switching to chemotherapy combined with bevacizumab resulted in a partial response and allowed for successful surgical intervention.
  • Postoperative pathology confirmed significant tumor regression and downstaging.
Interpretation:

Limitations:
  • The case is a single patient report, limiting generalizability.
  • There is a lack of prospective data on the safety and efficacy of the treatment approach in this specific patient population.
Conclusion:

This case illustrates the treatment challenges for advanced NSCLC in patients with active autoimmune diseases.

Original Source(s)

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

  • by Junfeng Ma, Peng Yan, Chonghua Liu, Yuanyuan Wang

  • June 8, 2026

Related Content

An ASCO preview: What to watch for at cancer research’s big meeting

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III